Gary M. Owens Sells 21,000 Shares of Mesa Laboratories, Inc. (NASDAQ:MLAB) Stock

Mesa Laboratories, Inc. (NASDAQ:MLAB - Get Free Report) CEO Gary M. Owens sold 21,000 shares of the company's stock in a transaction that occurred on Wednesday, March 19th. The shares were sold at an average price of $123.91, for a total value of $2,602,110.00. Following the completion of the sale, the chief executive officer now directly owns 43,337 shares in the company, valued at approximately $5,369,887.67. The trade was a 32.64 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Mesa Laboratories Price Performance

Mesa Laboratories stock traded down $5.08 during mid-day trading on Friday, hitting $119.57. 54,021 shares of the company were exchanged, compared to its average volume of 38,249. The company has a debt-to-equity ratio of 0.61, a current ratio of 0.71 and a quick ratio of 0.53. Mesa Laboratories, Inc. has a 12-month low of $83.68 and a 12-month high of $155.12. The business's 50 day simple moving average is $137.22 and its two-hundred day simple moving average is $129.21. The company has a market capitalization of $649.72 million, a P/E ratio of -2.58 and a beta of 0.82.

Mesa Laboratories (NASDAQ:MLAB - Get Free Report) last announced its earnings results on Tuesday, February 4th. The medical instruments supplier reported $2.07 earnings per share for the quarter, beating the consensus estimate of $1.41 by $0.66. Mesa Laboratories had a negative net margin of 104.92% and a positive return on equity of 30.23%. Analysts forecast that Mesa Laboratories, Inc. will post 8 earnings per share for the current fiscal year.

Mesa Laboratories Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Monday, March 17th. Investors of record on Friday, February 28th were given a dividend of $0.16 per share. The ex-dividend date of this dividend was Friday, February 28th. This represents a $0.64 dividend on an annualized basis and a yield of 0.54%. Mesa Laboratories's dividend payout ratio (DPR) is currently -1.38%.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of MLAB. Wellington Management Group LLP acquired a new stake in shares of Mesa Laboratories during the fourth quarter worth $1,888,000. Mackenzie Financial Corp increased its stake in shares of Mesa Laboratories by 26.1% during the 4th quarter. Mackenzie Financial Corp now owns 7,537 shares of the medical instruments supplier's stock valued at $994,000 after acquiring an additional 1,560 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in shares of Mesa Laboratories by 91.0% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 19,292 shares of the medical instruments supplier's stock worth $2,544,000 after acquiring an additional 9,189 shares during the period. Squarepoint Ops LLC purchased a new stake in Mesa Laboratories in the fourth quarter valued at approximately $293,000. Finally, Select Equity Group L.P. grew its stake in shares of Mesa Laboratories by 5.3% during the 4th quarter. Select Equity Group L.P. now owns 13,711 shares of the medical instruments supplier's stock valued at $1,808,000 after buying an additional 684 shares during the period. 90.60% of the stock is currently owned by institutional investors and hedge funds.

Mesa Laboratories Company Profile

Mesa Laboratories, Inc develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. The Sterilization and Disinfection Control segment offers biological, chemical, and cleaning indicators, used to assess the effectiveness of sterilization decontamination, disinfection, and cleaning processes in the pharmaceutical, medical device, and healthcare industries.